（编辑 任世碧） 证券日报网讯 12月25日，晨光生物在互动平台回答投资者提问时表示，公司在中药业务领域稳扎稳 打，建有国家药品GMP认证中药车间，可以批量化生产银杏叶片、板蓝根颗粒、复方丹参片、胃灵颗 粒、柏子养心丸等产品。目前已有银杏叶片、丹参配方颗粒、益母草配方颗粒、黄芪配方颗粒等中标集 采。 ...

Core Viewpoint - The nationwide governance of traditional Chinese medicine (TCM) pricing is intensifying, marking a shift from a "policy safe haven" to a "transparent competitive pool," indicating the TCM industry is entering a "cost + efficacy" dual pricing era [1][11][12] Group 1: Price Governance Actions - Multiple regions, including Inner Mongolia, Hebei, Ningxia, Jilin, and Guangxi, have initiated special governance on TCM prices, requiring companies to adjust prices of products deemed excessively high [1][3] - The Guangxi Drug Group Procurement Service Platform announced a governance notice targeting 169 high-priced TCMs, mandating price adjustments based on the "minimum daily cost" within the province [3][4] - A total of 123 TCMs were identified with price discrepancies, with some exceeding the minimum daily treatment cost by over 915 times [3][4] Group 2: Industry Impact and Future Outlook - The governance is expected to pressure companies that have relied on high pricing and marketing costs, pushing them to focus on cost control, process innovation, and genuine clinical value [1][9] - The combination of "volume-based procurement + price governance" is seen as a key path to standardizing drug prices, addressing unreasonable premiums in the distribution chain [11] - Long-term, companies with strong compliance and cost advantages are likely to dominate the market, while smaller firms may face elimination risks if they cannot achieve scale and quality standardization [12] Group 3: Specific Products and Companies Affected - Notable TCM products such as Xiao Chai Hu Granules, Niu Huang Jie Du Pian, and Ban Lan Gen Granules are included in the governance list, with specific pricing adjustments mandated [8][9] - Well-known companies like Shandong Hongjitang Pharmaceutical Group and Taiji Group's subsidiaries are among those named in the governance actions [8][11] - A-share listed company Keyuan Pharmaceutical is planning to acquire 99.42% of Hongjitang, indicating potential consolidation in the industry [8]